Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH)

PHASE2CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

May 5, 2017

Primary Completion Date

October 20, 2020

Study Completion Date

October 20, 2020

Conditions
Infantile Hemangioma
Interventions
DRUG

0.25% Timolol Maleate Gel Forming Solution

50:50 Randomized 0.25% Timolol Maleate Gel Forming Solution

DRUG

0.5% Timolol Maleate Gel Forming Solution

50:50 Randomized 0.5% Timolol Maleate Gel Forming Solution

Trial Locations (12)

10032

Columbia University Medical Center, New York

19104

Children's Hospital of Philadephia, Philadelphia

21287

Johns Hopkins Medical Center, Baltimore

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

46202

Indiana University Health, Indianapolis

53226

Medical College of Wisconsin, Milwaukee

55905

Mayo Clinic, Rochester

60611

Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago

75605

DCOL Center for Clinical Research, Longview

77030

The University of Texas Medical School at Houston, Houston

02115

Boston Children's Hospital, Boston

03756

Dartmouth-Hitchcock Medical Center, Lebanon

All Listed Sponsors
collaborator

The Emmes Company, LLC

INDUSTRY

collaborator

National Institutes of Health (NIH)

NIH

lead

Kanecia Obie Zimmerman

OTHER

NCT02913612 - Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH) | Biotech Hunter | Biotech Hunter